mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions : Current Evidence and Suggested Approach
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved..
The U.S. Food and Drug Administration (FDA) has recently issued an Emergency Use Authorization (EUA) for 2 highly effective coronavirus disease 2019 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. This has brought hope to millions of Americans in the midst of an ongoing global pandemic. The FDA EUA guidance for both vaccines is to not administer the vaccine to individuals with a known history of a severe allergic reaction (eg, anaphylaxis) to any component of the COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) additionally advises individuals with a history of an immediate allergic reaction to a vaccine or injectable or any history of anaphylaxis be observed for 30 minutes after COVID-19 vaccination. All other individuals should be observed for 15 minutes after COVID-19 vaccination. Staff at vaccine clinics must be able to identify and manage anaphylaxis. Post-FDA EUA, despite very strong safety signals in both phase 3 trials, reports of possible allergic reactions have raised public concern. To provide reassurance and support during widespread global vaccination, allergists must offer clear guidance to individuals based on the best information available, but also in accordance with the broader recommendations of regulatory agencies. This review summarizes vaccine allergy epidemiology and proposes drug and vaccine allergy expert opinion informed risk stratification for Allergy specialist use in conjunction with guidance of public health and regulatory authorities. The risk stratification schema guide care for (1) individuals with different allergy histories to safely receive their first mRNA COVID-19 vaccine and (2) individuals who develop a reaction to their first dose of mRNA COVID-19 vaccine.
| Errataetall: |
CommentIn: J Allergy Clin Immunol Pract. 2021 Apr;9(4):1438-1441. - PMID 33529722 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 9(2021), 4 vom: 25. Apr., Seite 1423-1437 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Banerji, Aleena [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.04.2021 Date Revised 13.12.2023 published: Print-Electronic CommentIn: J Allergy Clin Immunol Pract. 2021 Apr;9(4):1438-1441. - PMID 33529722 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2020.12.047 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319524884 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319524884 | ||
| 003 | DE-627 | ||
| 005 | 20231227130419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2020.12.047 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1224.xml |
| 035 | |a (DE-627)NLM319524884 | ||
| 035 | |a (NLM)33388478 | ||
| 035 | |a (PII)S2213-2198(20)31411-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Banerji, Aleena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions |b Current Evidence and Suggested Approach |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2021 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Allergy Clin Immunol Pract. 2021 Apr;9(4):1438-1441. - PMID 33529722 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The U.S. Food and Drug Administration (FDA) has recently issued an Emergency Use Authorization (EUA) for 2 highly effective coronavirus disease 2019 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. This has brought hope to millions of Americans in the midst of an ongoing global pandemic. The FDA EUA guidance for both vaccines is to not administer the vaccine to individuals with a known history of a severe allergic reaction (eg, anaphylaxis) to any component of the COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) additionally advises individuals with a history of an immediate allergic reaction to a vaccine or injectable or any history of anaphylaxis be observed for 30 minutes after COVID-19 vaccination. All other individuals should be observed for 15 minutes after COVID-19 vaccination. Staff at vaccine clinics must be able to identify and manage anaphylaxis. Post-FDA EUA, despite very strong safety signals in both phase 3 trials, reports of possible allergic reactions have raised public concern. To provide reassurance and support during widespread global vaccination, allergists must offer clear guidance to individuals based on the best information available, but also in accordance with the broader recommendations of regulatory agencies. This review summarizes vaccine allergy epidemiology and proposes drug and vaccine allergy expert opinion informed risk stratification for Allergy specialist use in conjunction with guidance of public health and regulatory authorities. The risk stratification schema guide care for (1) individuals with different allergy histories to safely receive their first mRNA COVID-19 vaccine and (2) individuals who develop a reaction to their first dose of mRNA COVID-19 vaccine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allergic reactions | |
| 650 | 4 | |a Allergy | |
| 650 | 4 | |a Anaphylaxis | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Polyethylene glycol | |
| 650 | 4 | |a Polysorbate | |
| 650 | 4 | |a Risk stratification | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a mRNA | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 700 | 1 | |a Wickner, Paige G |e verfasserin |4 aut | |
| 700 | 1 | |a Saff, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Cosby A |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Lacey B |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Aidan A |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfson, Anna R |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Blumenthal, Kimberly G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 9(2021), 4 vom: 25. Apr., Seite 1423-1437 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:4 |g day:25 |g month:04 |g pages:1423-1437 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2020.12.047 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 4 |b 25 |c 04 |h 1423-1437 | ||